Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Fusion Pharmaceuticals Inc. | fusn-ex322_7.htm |
| EX-31.2 - EX-31.2 - Fusion Pharmaceuticals Inc. | fusn-ex312_8.htm |
| EX-31.1 - EX-31.1 - Fusion Pharmaceuticals Inc. | fusn-ex311_9.htm |
| EX-23.1 - EX-23.1 - Fusion Pharmaceuticals Inc. | fusn-ex231_944.htm |
| EX-10.24 - EX-10.24 - Fusion Pharmaceuticals Inc. | fusn-ex1024_1037.htm |
| EX-10.22 - EX-10.22 - Fusion Pharmaceuticals Inc. | fusn-ex1022_1179.htm |
| EX-10.11 - EX-10.11 - Fusion Pharmaceuticals Inc. | fusn-ex1011_897.htm |
| EX-10.8 - EX-10.8 - Fusion Pharmaceuticals Inc. | fusn-ex108_898.htm |
| EX-4.3 - EX-4.3 - Fusion Pharmaceuticals Inc. | fusn-ex43_899.htm |
| 10-K - 10-K - Fusion Pharmaceuticals Inc. | fusn-10k_20201231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Fusion Pharmaceuticals Inc. (the “Company”) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
(1) |
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
|
Date: March 25, 2021 |
|
By: |
/s/ John Valliant |
|
|
|
|
John Valliant |
|
|
|
|
Chief Executive Officer |